Necrosis of femoral head
Conditions
Interventions
Experimental group:Extracorporeal shock wave therapy(ESWT)
Control group:Celecoxib is taken orally
Sponsors
The Third Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. MRI imaging results were used to diagnose ARCO stage I-IV of femoral head necrosis. MRI imaging results in the first 4 weeks of the screening stage were available; 3. Unwilling to accept surgical treatment, agree not to use non-research treatment related to hip pain during the study period, such as drugs not related to the study and other physical therapy; 4. Voluntarily participate in the clinical trial, comply with the requirements of the clinical trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe heart disease, arrhythmia and hypertension; 2. A heart pacemaker is installed; 3. Patients with uncured hemorrhagic disease and coagulation dysfunction; 4. The use of anti-immune agents; 5. All kinds of tumor patients on the shockwave path; 6. Patients with thrombosis on the shockwave path; 7. All landowners pregnant women; 8. Shock wave incidence site of local infection and skin ulceration patients; 9. Patients with joint fluid leakage; 10. Attending researchers decide that they are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hip pain improvement rate at 2 weeks after completion of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Harris score;Visual Analogue Scale;Western Ontario and McMaster Universities Osteoarthritis Index;Quality of life questionnaire; | — |
Countries
China
Contacts
Public ContactXing Gengyan
The Third Medical Center of the PLA General Hospital
Outcome results
None listed